Mark Kotter

Mark Kotter (born 1971) is a Canadian neurosurgeon, biologist, and entrepreneur. He is the founder and CEO of the biotechnology company bit.bio and the co-founder of the cultured meat company Meatable. Provided by Wikipedia
Showing 1 - 4 results of 4 for search 'Mark Kotter', query time: 0.01s Refine Results
  1. 1
    Drug treatment alters performance in a neural microphysiological system of information processing

    Drug treatment alters performance in a neural microphysiological system of information processing by Bradley Watmuff, Forough Habibollahi, Candice Desouza, Moein Khajehnejad, Alon Loeffler, Koby Baranes, Noah Poulin, Mark Kotter, Brett J. Kagan

    Published 2025-06-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Recovery priorities in degenerative cervical myelopathy: a cross-sectional survey of an international, online community of patients

    Recovery priorities in degenerative cervical myelopathy: a cross-sectional survey of an international, online community of patients by Benjamin Davies, Mark Kotter, Oliver Mowforth, Iwan Sadler, Bizhan Aarabi, Jefferson R Wilson, Robert Grossman, Michael G Fehlings, Brian Kwon, Shekar Kurpad, James S Harrop

    Published 2019-10-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Cerebrospinal fluid pressure dynamics as a biomechanical marker for quantification of spinal cord compression: Conceptual framework and systematic review of clinical trials

    Cerebrospinal fluid pressure dynamics as a biomechanical marker for quantification of spinal cord compression: Conceptual framework and systematic review of clinical trials by Najmeh Kheram, Madeleine A. Bessen, Claire F. Jones, Benjamin M. Davies, Mark Kotter, Mazda Farshad, Markus Hupp, Daniel Nanz, Patrick Freund, Martin Schubert, Vartan Kurtcuoglu, Armin Curt, Carl M. Zipser

    Published 2025-01-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Can screening for degenerative cervical myelopathy (SCREEN-DCM) be effectively undertaken based on signs, symptoms and known risk factors? Rationale and research protocol for a prospective, multicentre, observational study

    Can screening for degenerative cervical myelopathy (SCREEN-DCM) be effectively undertaken based on signs, symptoms and known risk factors? Rationale and research protocol for a pro... by Benjamin Davies, Mark Kotter, Granit Molliqaj, Enrico Tessitore, Karl Schaller, Teresa Somma, Aria Nouri, Renato Gondar, Joseph S Cheng, Paolo Cappabianca, Alexandre Lavé, Gianpaolo Jannelli, Allan Martin, Justin Virojanapa, Carmen L A Vleggeert-Lankamp, Valerie ter Wengel, Torstein Meling

    Published 2022-07-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: